Op De Beeck, Katrijn, Vermeersch, Pieter, Verschueren, Patrick et al. · Autoimmunity reviews · 2011 · DOI
This study compared two different blood tests for detecting antinuclear antibodies (proteins the immune system sometimes makes against the body's own cells). Researchers tested these methods in people with autoimmune diseases, healthy people, ME/CFS patients, and other disease controls. The newer solid phase test was better at correctly identifying people with certain autoimmune diseases, though both tests rarely showed false positives in ME/CFS patients.
This study is relevant to ME/CFS research because it provides baseline data on antinuclear antibody prevalence in ME/CFS patients (showing <4% reactivity), helping distinguish ME/CFS from autoimmune connective tissue diseases. Understanding which diagnostic tests accurately differentiate ME/CFS from autoimmune conditions is important for proper patient classification in research and clinical care.
This study does not prove that antinuclear antibodies cause or contribute to ME/CFS pathogenesis—it only describes their presence or absence. It also does not establish whether antinuclear antibodies play any functional role in either ME/CFS or rheumatic disease; it is purely a diagnostic performance comparison. The cross-sectional design cannot determine whether antibody status changes over time or precedes symptom development.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →